Prevalence, Duration and Severity of Parkinson's Disease in Germany: A Combined Meta-Analysis from Literature Data and Outpatient Samples

Abstract

Background: Epidemiological data on the prevalence of Parkinson's disease (PD) in Germany are limited. The aims of this study were to estimate the age- and gender-specific prevalence of PD in Germany as well as the severity and illness duration. Summary: A systematic literature search was performed in 5 different databases. European studies were included if they reported age- and gender-specific numbers of prevalence rates of PD. Meta-analytic approaches were applied to derive age- and gender-specific pooled prevalence estimates. Data of 4 German outpatient samples were incorporated to calculate the proportion of patients with PD in Germany grouped by Hoehn and Yahr (HY) stages and disease duration. In the German population, 178,169 cases of PD were estimated (prevalence: 217.22/100,000). The estimated relative illness duration was 40% with less than 5 years, 31% with 5-9 years, and 29% with more than 9 years. The proportions for different HY stages were estimated at 13% (I), 30% (II), 35% (III), 17% (IV), and 4% (V), respectively. Key Message: We provide an up-to-date estimation of age- and gender-specific as well as severity-based prevalence figures for PD in Germany. Further community studies are needed to estimate population-based severity distributions and distributions of non-motor symptoms in PD.

Trends in der Prävalenz von Demenz und Parkinson – Eine Analyse auf Basis aller gesetzlich versicherten Personen im Alter 65+in Deutschland zwischen 2009 und 2012

“…im Jahr 2040 noch den wahren Anstieg unterschätzen würden. Für Deutschland schwanken die Angaben zwischen 178 169 [11], bzw. 246 000 und 296 000 [12] Erkrankten.…”

Evaluation of Therapeutics for Severely Debilitating or Life‐Threatening Diseases or Conditions: Defining Scope to Enable Global Guidance Development

“…A clear line between non‐SDLT and SDLT exists in the first example, while the transition between non‐SDLT to SDLT may be gradual in the second example. In both images, size of the boxes ( a ) and triangles ( b ) are proportional to the prevalence of the disease population: the prevalence of SLE and LN (lupus nephritis) in the United States was estimated to be 313,436 and 63,256 patients, respectively, based on a 2013 meeting abstract; the prevalence of Parkinson's disease and advanced Parkinson's disease was estimated to be 6.1 million and 1.3 million cases worldwide, respectively, in 2016 …”

“…At this stage, the term "advanced Parkinson's disease" (APD ) may be applied. The prevalence of APD is estimated to be approximately 1.3 million cases worldwide, inclusive of an estimated 148,500 cases in the United States …”

“…The prevalence of APD is estimated to be approximately 1.3 million cases worldwide, inclusive of an estimated 148,500 cases in the United States. 22,23 Not all stages of PD should be considered SDLTs as patients with mild symptoms may be functional and independent and not require dopaminergic therapy or their condition may be responsive to available therapies. However, APD is considered an SDLT (as outlined in Table 2) based on severe disability of the patients who are completely dependent on caregivers, the potential for irreversible morbidity or death from recurrent falls or choking, progressive nature of the disease, and absence of adequate therapies.…”

Osteoporose beim Idiopathischem Parkinson-Syndrom: Risikopatienten erkennen, diagnostizieren und richtig behandeln

“…Siebzig Prozent der Patienten sind bei der Erstmanifestation älter als 55 Jahre. Im Jahr 2017 wurde die Zahl der IPS-Erkrankten in Deutschland auf ungefähr 180.000 bis 220.000 geschätzt [14], etwa 60 % sind männlich [15]. Nach einer Analyse von Dorsay et.…”